[1]
Vaideeswar P, Shah R. Zygomycotic infective endocarditis in pregnancy. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology. 2017 May-Jun:28():28-30. doi: 10.1016/j.carpath.2017.02.007. Epub 2017 Mar 3
[PubMed PMID: 28288409]
[2]
Sasaki T, Mineta M, Kobayashi K, Ando M, Obata M. Zygomycotic invasion of the central nervous system. Japanese journal of radiology. 2010 Jun:28(5):376-80. doi: 10.1007/s11604-010-0435-z. Epub 2010 Jun 30
[PubMed PMID: 20585927]
[3]
Goel S, Carter JE, Culpepper M, Kahn AG. Primary renal zygomycotic infarction mimicking renal neoplasia in an immunocompetent patient. The American journal of the medical sciences. 2009 Oct:338(4):330-3. doi: 10.1097/MAJ.0b013e3181aa30d0. Epub
[PubMed PMID: 19701078]
[4]
Jain D, Kumar Y, Vasishta RK, Rajesh L, Pattari SK, Chakrabarti A. Zygomycotic necrotizing fasciitis in immunocompetent patients: a series of 18 cases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2006 Sep:19(9):1221-6
[PubMed PMID: 16741524]
Level 3 (low-level) evidence
[5]
Jenks JD, Mehta SR, Hoenigl M. Broad spectrum triazoles for invasive mould infections in adults: Which drug and when? Medical mycology. 2019 Apr 1:57(Supplement_2):S168-S178. doi: 10.1093/mmy/myy052. Epub
[PubMed PMID: 30816967]
[6]
Koehler P, Mellinghoff SC, Lagrou K, Alanio A, Arenz D, Hoenigl M, Koehler FC, Lass-Flörl C, Meis JF, Richardson M, Cornely OA. Development and validation of the European QUALity (EQUAL) score for mucormycosis management in haematology. The Journal of antimicrobial chemotherapy. 2019 Jun 1:74(6):1704-1712. doi: 10.1093/jac/dkz051. Epub
[PubMed PMID: 30770712]
Level 2 (mid-level) evidence
[7]
Durga CS, Gupta N, Soneja M, Bhatt M, Xess I, Jorwal P, Singh G, Ray A, Nischal N, Ranjan P, Biswas A, Wig N. Invasive fungal infections in critically ill patients: A prospective study from a tertiary care hospital in India. Drug discoveries & therapeutics. 2018:12(6):363-367. doi: 10.5582/ddt.2018.01068. Epub
[PubMed PMID: 30674771]
[8]
Hoenigl M, Gangneux JP, Segal E, Alanio A, Chakrabarti A, Chen SC, Govender N, Hagen F, Klimko N, Meis JF, Pasqualotto AC, Seidel D, Walsh TJ, Lagrou K, Lass-Flörl C, Cornely OA, European Confederation of Medical Mycology (ECMM). Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses. 2018 Nov:61(11):885-894. doi: 10.1111/myc.12836. Epub 2018 Aug 28
[PubMed PMID: 30086186]
[9]
Jenks JD, Salzer HJ, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug design, development and therapy. 2018:12():1033-1044. doi: 10.2147/DDDT.S145545. Epub 2018 Apr 30
[PubMed PMID: 29750016]
[10]
Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Medical mycology. 2018 Apr 1:56(suppl_1):93-101. doi: 10.1093/mmy/myx101. Epub
[PubMed PMID: 29538730]
[11]
Cooper JD, Gotoff RA, Foltzer MA, Carter RA, Walsh TJ. Mediastinal Mucormycosis: Case report, review of literature and treatment with continuous liposomal amphotericin B irrigation. Mycoses. 2019 Sep:62(9):739-745. doi: 10.1111/myc.12922. Epub 2019 May 23
[PubMed PMID: 31044442]
Level 3 (low-level) evidence
[12]
Kashyap S, Bernstein J, Ghanchi H, Bowen I, Cortez V. Diagnosis of Rhinocerebral Mucormycosis by Treatment of Cavernous Right Internal Carotid Artery Occlusion With Mechanical Thrombectomy: Special Case Presentation and Literature Review. Frontiers in neurology. 2019:10():264. doi: 10.3389/fneur.2019.00264. Epub 2019 Mar 26
[PubMed PMID: 30972005]
Level 3 (low-level) evidence
[13]
Valentine JC, Morrissey CO, Tacey MA, Liew D, Patil S, Peleg AY, Ananda-Rajah MR. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016. BMC infectious diseases. 2019 Mar 21:19(1):274. doi: 10.1186/s12879-019-3901-y. Epub 2019 Mar 21
[PubMed PMID: 30898090]
[14]
Farina C, Marchesi G, Passera M, Diliberto C, Russello G, Favalli A. In vitro activity of Amphotericin B against zygomycetes isolated from deep mycoses: a comparative study between incubation in aerobic and hyperbaric atmosphere. Medical mycology. 2012 May:50(4):427-32. doi: 10.3109/13693786.2011.614964. Epub 2011 Sep 28
[PubMed PMID: 21954953]
Level 2 (mid-level) evidence
[15]
Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2016 Sep:22(9):811.e1-811.e8. doi: 10.1016/j.cmi.2016.03.029. Epub 2016 Apr 13
[PubMed PMID: 27085727]